Aripiprazole Microspheres Sustained Release For Injection(Hulii Pharma)

注射用阿立哌唑缓释微球（辉粒药业）

Report date: 2025/07/31 15:01:38

Base Information

Drug NameAripiprazole Microspheres Sustained Release For Injection(Hulii Pharma)
Drug Alias Name阿利哌唑阿立派唑注射用阿立哌唑缓释微球（2.2类改良型）
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor agonistsDopamine D4 receptor antagonists +[9] 
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor +[9] 
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHulii Pharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHulii Pharmaceutical (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG